Price Momentum and Recent Performance
On 21 Sep 2026, Shukra Pharmaceuticals closed at ₹55.96, up 3.13% from the previous close of ₹54.26. The intraday range saw a low of ₹54.04 and a high of ₹57.75, indicating increased volatility and buying interest. The stock remains below its 52-week high of ₹65.26 but comfortably above its 52-week low of ₹26.30, underscoring a strong recovery trajectory over the past year.
Comparing returns against the benchmark Sensex reveals Shukra’s outperformance across multiple timeframes. Over the past week, the stock gained 3.74% while the Sensex declined 0.65%. The one-month return is particularly impressive at 34.23%, contrasting with a 3.81% fall in the Sensex. Year-to-date, Shukra is down 5.55%, but this still outpaces the Sensex’s 12.82% decline. Over longer horizons, the stock’s returns are extraordinary, with an 82.64% gain over one year versus a 10.50% loss in the Sensex, and a staggering 13,223.81% return over five years compared to Sensex’s 25.89%.
Technical Indicator Analysis
The technical landscape for Shukra Pharmaceuticals is nuanced. The overall trend has softened from bullish to mildly bullish, reflecting a more cautious market stance. The Moving Average Convergence Divergence (MACD) indicator presents a mixed picture: weekly MACD remains bullish, signalling positive momentum in the short term, while the monthly MACD has turned mildly bearish, suggesting potential medium-term headwinds.
The Relative Strength Index (RSI) adds further complexity. On a weekly basis, the RSI is bearish, indicating that the stock may be experiencing short-term selling pressure or is approaching overbought conditions. However, the monthly RSI shows no clear signal, implying a neutral momentum over the longer term.
Bollinger Bands provide a more optimistic outlook, with both weekly and monthly readings bullish. This suggests that price volatility is accompanied by upward momentum, and the stock is trading near the upper band, often a sign of strength. Daily moving averages reinforce this bullish stance, indicating that recent price action is supported by positive short-term trends.
The Know Sure Thing (KST) oscillator aligns with the MACD, showing weekly bullishness but a mildly bearish monthly trend. Dow Theory analysis reveals no clear weekly trend but a mildly bullish monthly trend, signalling that the broader market sentiment may be cautiously positive. On-Balance Volume (OBV) remains neutral on both weekly and monthly scales, indicating that volume trends have not decisively confirmed price movements.
Fast mover alert! This Large Cap from Automobiles - Passeenger just qualified for our Momentum list with stellar technical indicators. Strike while the iron is hot!
- - Recent Momentum qualifier
- - Stellar technical indicators
- - Large Cap fast mover
Mojo Score and Rating Revision
MarketsMOJO’s proprietary Mojo Score for Shukra Pharmaceuticals currently stands at 62.0, categorising the stock as a Hold. This represents a downgrade from the previous Buy rating issued on 15 Sep 2026. The downgrade reflects the tempered technical momentum and mixed indicator signals, suggesting investors should exercise caution despite the stock’s strong historical returns and recent price gains.
As a micro-cap entity within the Pharmaceuticals & Biotechnology sector, Shukra’s market capitalisation grade remains micro-cap, which inherently carries higher volatility and risk compared to larger peers. The downgrade aligns with a prudent approach to risk management, especially given the divergence in weekly and monthly technical indicators.
Long-Term Performance Context
Shukra Pharmaceuticals’ long-term performance is exceptional, with a 10-year return of 17,951.61%, vastly outperforming the Sensex’s 159.78% over the same period. This extraordinary growth underscores the company’s ability to generate shareholder value over extended horizons, driven by innovation and sector tailwinds in Pharmaceuticals & Biotechnology.
However, the recent technical signals suggest that the pace of momentum may be moderating. Investors should weigh the stock’s impressive historical gains against the current technical caution flags, particularly the bearish weekly RSI and mildly bearish monthly MACD and KST indicators.
Shukra Pharmaceuticals Ltd or something better? Our SwitchER feature analyzes this micro-cap Pharmaceuticals & Biotechnology stock and recommends superior alternatives based on fundamentals, momentum, and value!
- - SwitchER analysis complete
- - Superior alternatives found
- - Multi-parameter evaluation
Investor Takeaway and Outlook
For investors considering Shukra Pharmaceuticals, the current technical landscape advises a balanced approach. The daily moving averages and Bollinger Bands indicate short-term bullishness, supported by a strong weekly MACD and KST. However, the bearish weekly RSI and mildly bearish monthly MACD and KST suggest that momentum may be slowing, warranting caution.
The stock’s recent 3.13% gain and strong one-month return of 34.23% highlight positive price action, yet the downgrade to Hold signals that the risk-reward profile is less favourable than before. Given the micro-cap status and sector volatility, investors should monitor technical indicators closely and consider diversification or alternative opportunities within the Pharmaceuticals & Biotechnology space.
Overall, Shukra Pharmaceuticals remains a compelling story with impressive long-term returns, but the current technical signals counsel a more measured stance amid mixed momentum cues.
Get 33% Off on our 1 Year Plan - Limited Period Only! Start Today
